Myocardial-salvaging Effects of a Novel Polyherbal Combination with Dipeptidyl Peptidase-4 Inhibitory Activity.

Background: Some of the medicinal plants possess dipeptidyl peptidase-4 (DPP-4) inhibitory properties and could overcome the limitations of synthetic DPP-4 inhibitors.

Aim: We evaluated the anti-diabetic and myocardial-salvaging effects of a novel polyherbal combination (PHC) containing Terminalia arjuna, Commiphora mukul and Emblica officinalis in rats.

Methods: Male Wistar rats weighing 150-200 g and 8-10 weeks were randomised to negative control (NC; no disease induction/treatment), disease control (DC; disease induction but no treatment), vildagliptin (disease induction and treatment with vildagliptin 10 mg/kg) or PHC1000 (disease induction and treatment with PHC 1000 mg/kg).

Bio-standardization and development of a unique polyherbal formulation with dipeptidyl peptidase -IV inhibitory activity for type 2 diabetes mellitus.

Medicinal herbs may provide an alternative source of Dipeptidyl peptidase -IV (DPP-IV) Inhibitors, particularly in light of mounting evidence of high costs and adverse drug reactions associated with synthetic DPP-IV Inhibitors. DPP-IV inhibitory activity of medicinal plants , and was elucidated in previous investigations from our lab. The goal of this work was to develop a polyherbal tablet including these medicinal plants with DPP-IV inhibitory action, conduct bio-standardization investigations, and test its anti-diabetic benefits in the streptozotocin model of Type 2 diabetes.